$CRBP News

Corbus Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; Co. To Offer And Sell Common Stock Up To $127.50M Through Jefferies

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate

Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript

Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO - Slideshow

Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug Conjugate

Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44

Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout